We are delighted to let you know that the 22nd World Congress on Toxicology and Pharmacology during July 14-15, 2020 at Kyoto, Japan was very much successful. Toxicology Congress 2020 offered a unique stage to present and know the most recent updates in the field of Toxicology and Pharmacology covering wide areas of interest. Why Toxicology Congress 2021? At Toxicology Congress 2021 you can meet the world’s leading toxicologists, pharmacologists, clinical research professionals, biochemists and also the industrialists who will provide you with the latest innovations and scientific approaches thus, help you in widening your scientific knowledge. The topics of the Congress will reflect the recent advances, current trends, future trends and new approaches in Toxicology and Pharmacology. The congress will cover among others: Mechanisms and modes of action of various toxins, Clinical and Forensic toxicology, Emerging in vitro models, Medicine Development and Safety Testing, Regulatory toxicology and last but not least, a broad scope of pharmacology and toxicology in different fields.
The success of the Gastroenterology Conference 2021 has given us the prospect to bring the gathering one more time. Allied Academies hosted the “4th International Conference on Gastroenterology and Hepatology, Exploring Novel Innovations in the field of Gastroenterology and Hepatology” during March 25-26, 2021 at Holiday Inn Amsterdam - Arena Towers, Amsterdam, Netherlands. The conference was focused on Gastroenterology, Hepatology with the theme “Exploring Novel Innovations in the field of Gastroenterology and Hepatology”. The meeting engrossed a vicinity of comprehensive discussions on novel subjects Molecular GastroenterologyColorectal and Intestinal Disorders, Gallstones and Bile Duct StonesEsophageal Diseases,
Drug manufacturers are incorporating ADME toxicity testing in early phases of drug development to meet the increasing demand to control drug toxicities which is expected to drive growth of this market. Introduction of technologically advanced computer based testing models are further improving growth of this market. ADME toxicity testing market is studied in reference to in-vitro and in-vivo technologies. In-Owing to increasing ethical concerns over animal use in clinical trials, in-vivo toxicity testing methods are gaining popularity. Use of ADME toxicity computer modelling is expected to rise due to its capability of effective cost reduction, due to early ADME toxicity prediction and other associated benefits related to increase throughput screening
Best Speaker Award This Speaker award seeks to recognise an individual who have demonstrated excellence when it comes to elaborating the presentation with an ease in Speaker Sessions through an on-going high-quality standard of his experience. Best Research Award This Research award seeks to appreciate an individual or team who have displayed excellence when it comes to research in their respective area, with high-quality standard of their efforts to make it possible for new innovation. Best Young Researcher AwardThis Young Researcher award seeks to encourage students in taking active part in the International Science platform to sharpen their skills and knowledge in their early stage of career graph. Best Poster AwardThis Poster Award seeks to appreciate an individual who have displayed excellence when it comes to expose research in poster presentation category, with high-quality standard of their efforts to make it possible for new ideas & innovation. Best E-Poster AwardThis E-Poster Award seeks to appreciate an individual who have displayed excellence when it comes to expose research in E-poster
Allied Academies is very proud to announce the Young Scientist Awards at Gastroenterology and Hepatology 2020 Conference to explore and honor the research ideas related to new advances in the field of both medical and engineering to improve health and treatment and also additional transformation. We hope that you will grasp this academic occasion to revitalize the enduring connections and flash with new peers around the in the young minds of Researchers, PhD Students, Post Graduate Students, Investigators, Post-Doctoral Fellows, Trainees and Junior Faculty.
Clinical hepatology has recently gained a wider recognition among medical community owing to the advancements in liver biochemical investigations and with liver diseases now being increasingly recognized as a major threat to public health. Malnutrition, drug addiction, alcohol abuse and environmental pollution are prevalent across different regions of the world which are identified to be associated with risk factors of liver diseases. Liver diseases, if highly prevalent and if remain untreated, may lead to reduced longevity and productivity and can hamper the socioeconomic contribution.
Objective: Patients with nonalcoholic steatohepatitis (NASH) are at risk for developing cirrhosis and hepatic cancer. Currently, the definitive gold-standard method of diagnosing NASH is a liver biopsy, an invasive and costly method. Our objective was to compare three non-invasive methods of identifying NASH by using data on 10,007 subjects from NHANES III (1988–1994) to determine the prevalence and variables associated with NASH, as defined by each non-invasive method. Methods: We used ultrasound data to identify subjects with moderate-to-severe hepatic steatosis, of whom we identified the NASH population using either the HAIR score, the NASH liver fat score, or the Gholam score, each of which had been validated with liver biopsy. We performed multinomial logistic regression to compare each NASH population to the normal population (those with no-to-mild hepatic steatosis). Results: We identified 1136 (9.5%) subjects as having NASH by at least one method and 219 (1.8%) were identified by all 3 methods. Independent of the non-invasive method used, Mexican-Americans (MA) had the highest prevalence of NASH. All three methods identified significant risk factors for NASH (p<0.05), including: elevated waist-to-hip ratio, elevated levels of C-peptide, total cholesterol, or C-reactive protein (CRP). Conclusion: We conclude that the combined non-invasive methods can help identify candidates with a high likelihood of being diagnosed with NASH. Health care providers can screen people with the combined non-invasive methods for the risk factors and identify candidates for interventions, including exercise and/or referral to biopsy.
Frailty is an unstable phenomenon affecting multiple physiological systems, resulting in decreased reserve and vulnerable outcomes. With ageing the prevalence of frailty seems to be increasing general population as well as with cirrhosis patients. Though research are undergoing on prognostic markers, gut microbes or pharmacology in hepatology, it should be extended to a proper definition for frailty its diagnostic tool and management. Frailty score should be considered along with MELD score as a routine assessment in patients waiting for liver transplantation. Malnutrition is a common complication of cirrhosis patients which may leads to frailty, even though frailty is seen in well-nourished patients. When normal dietary supplements become ineffective the need for nutritional supplements like Branched chain amino acids (BCAA) become necessary. Combining BCAAs along with exercise therapy have shown significant improvements for lower limb muscle strength and balance ability in frail and pre-frail cirrhotic patients since muscle wasting is a major concern for them.
Non-alcoholic Fatty Liver Disease (NAFLD) is highly prevalent in the developed world. The prevalence has been increasing over the past few decades in parallel with an increase in the metabolic syndrome. South Asia hosts some of the most populated cities in the world and recent studies suggest the prevalence of NAFLD in some of these areas to be comparable to the western world. Earlier diagnosis should prompt life style modifications and the use of appropriate medications to prevent progression to hepatic fibrosis. In this paper we present the commentary of a group of experts from Nepal regarding the routine clinical management of NAFLD in Nepal from their clinical experiences.
Objective: Patients with nonalcoholic steatohepatitis (NASH) are at risk for developing cirrhosis and hepatic cancer.Currently, the definitive gold-standard method of diagnosing NASH is a liver biopsy, an invasive and costly method.Our objective was to compare three non-invasive methods of identifying NASH by using data on 10,007 subjects from NHANES III (1988-1994) to determine the prevalence and variables associated with NASH, as defined by each non-invasive method. Methods:We used ultrasound data to identify subjects with moderate-to-severe hepatic steatosis, of whom we identified the NASH population using either the HAIR score, the NASH liver fat score, or the Gholam score, each of which had been validated with liver biopsy.We performed multinomial logistic regression to compare each NASH population to the normal population (those with no-to-mild hepatic steatosis). Results:We identified 1136 (9.5%) subjects as having NASH by at least one method and 219 (1.8%) were identified by all 3 methods.Independent of the non-invasive method used, Mexican-Americans (MA) had the highest prevalence of NASH.All three methods identified significant risk factors for NASH (p<0.05),including: elevated waist-to-hip ratio, elevated levels of C-peptide, total cholesterol, or C-reactive protein (CRP). Conclusion:We conclude that the combined non-invasive methods can help identify candidates with a high likelihood of being diagnosed with NASH.Health care providers can screen people with the combined non-invasive methods for the risk factors and identify candidates for interventions, including exercise and/or referral to biopsy.
